Humana Inc. (NYSE:HUM – Get Free Report) gapped up prior to trading on Friday after TD Cowen upgraded the stock from a hold rating to a buy rating. The stock had previously closed at $380.00, but opened at $392.54. TD Cowen now has a $485.00 price target on the stock, up from their previous price target of $430.00. Humana shares last traded at $397.0840, with a volume of 216,814 shares.
Other research analysts also recently issued reports about the stock. Royal Bank Of Canada set a $515.00 price objective on shares of Humana in a research report on Tuesday. HSBC cut Humana to a “hold” rating in a report on Thursday, July 30th. Barclays increased their price target on shares of Humana from $582.00 to $587.00 and gave the company an “overweight” rating in a research report on Monday, November 9th. Jefferies Financial Group reissued a “buy” rating and set a $420.00 target price on shares of Humana in a research report on Friday, November 6th. Finally, Evercore raised shares of Humana from an “in-line” rating to an “outperform” rating and set a $480.00 target price for the company in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $491.74.
Get Our Latest Stock Report on HUM
Insider Transactions at Humana
Key Stories Impacting Humana
Here are a few of the latest stories about HUM:
- Positive Sentiment: Morgan Stanley lifted its price target to $475 from $370, though it kept an “Equal Weight” rating. Morgan Stanley price target
- Neutral Sentiment: Humana is up more than 50% this year, but investors who bought three years ago remain underwater. The durability of the recovery may depend on Medicare Advantage growth, Star Ratings and the company’s December investor update. 247WallSt article
- Negative Sentiment: Zacks Research trimmed its Q3 2028 EPS estimate to $6.38 from $6.58, tempering the positive estimate revisions elsewhere. MarketBeat analyst estimates
Institutional Investors Weigh In On Humana
A number of large investors have recently bought and sold shares of HUM. Defiance ETFs LLC acquired a new stake in shares of Humana in the third quarter worth $201,000. DGS Capital Management LLC increased its position in Humana by 31.8% in the third quarter. DGS Capital Management LLC now owns 849 shares of the insurance provider’s stock worth $324,000 after buying an additional 205 shares during the period. Innovator Capital Management LLC bought a new stake in shares of Humana during the third quarter valued at approximately $2,546,000. Brown Financial Advisors increased its stake in Humana by 4.8% during the 3rd quarter. Brown Financial Advisors now owns 1,228 shares of the insurance provider’s stock valued at $468,000 after buying an additional 56 shares during the period. Finally, iSAM Funds UK Ltd acquired a new position in Humana during the third quarter worth about $305,000. Institutional investors and hedge funds own 92.38% of the company’s stock.
Humana Stock Performance
The stock has a market cap of $46.84 billion, a price-to-earnings ratio of 37.94, a price-to-earnings-growth ratio of 1.87 and a beta of 0.65. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.61. The company’s 50-day simple moving average is $409.49 and its 200-day simple moving average is $322.39.
Humana (NYSE:HUM – Get Free Report) last released its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.30. Humana had a net margin of 0.81% and a return on equity of 8.50%. The business had revenue of $41.16 billion for the quarter, compared to the consensus estimate of $40.87 billion. During the same period last year, the firm posted $3.24 earnings per share. The firm’s quarterly revenue was up 26.1% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.500- EPS. Analysts predict that Humana Inc. will post 9.64 EPS for the current fiscal year.
Humana Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Shareholders of record on Thursday, December 24th will be given a $0.8850 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Thursday, December 24th. Humana’s payout ratio is currently 34.44%.
About Humana
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Further Reading
- Five stocks we like better than Humana
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
